Clinical trials: SARS CoV 2 Virus
COVID-19
Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents
This is a specimen collection study intended to generate a biological specimen repository of samples from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults and adolescents ≥12 years old who will receive…
- Trial name
- CoVacSpec (NCT05252910)
- Where
- 32 sites in United States, Colombia and 5 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pharm-Olam, LLC
Mild to Moderate COVID-19
Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2 infection.
- Trial name
- NCT05620160
- Testing
- RAY1216
- Where
- China
- Volunteers
- 1,359 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
SARS CoV-2 Infection, Influenza -Like Illness
A Trial of Two Mask Systems in Preventing SARS CoV-2 in Healthcare Workers (HCW)
A cluster randomized trial will be conducted to evaluate the difference between an Acteev™ system (Acteev™ N95 masks YQD8008 during shifts+ Acteev™ fabric masks in community) and a standard system (standard N95 masks during…
- Trial name
- NCT05036941
- Testing
- Acteev™ Masks, Comparison Masks
- Where
- India
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Ascend Performance Materials
Healthy Participant
A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults
A study to learn how the study medicine called Ibuzatrelvir is taken up into the blood in healthy Chinese adults.
- Trial name
- NCT07235137
- Testing
- Ibuzatrelvir
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants
- Trial name
- NCT04532294
- Testing
- BGB DXP593
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BeiGene
COVID-19 Infection
An Open-Label Study of Apabetalone in Covid Infection
The primary objective of the study is to evaluate the safety and effect on clinical course of oral apabetalone in hospitalized subjects with Covid-19 infection
- Trial name
- NCT04894266
- Testing
- Apabetalone, Standard of care
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Resverlogix Corp
SARS-CoV-2
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection
SNG001 is an inhaled drug that contains a antiviral protein called interferon beta (IFN-β). IFN-β in produced in the lungs during viral lung infections.
- Trial name
- NCT04385095
- Testing
- SNG001
- Where
- 13 sites in United Kingdom
- Volunteers
- 221 people
- Sponsor
- Synairgen Research Ltd.
COVID-19
Portable Oxygen Concentrator (POC) Versus Standard of Care in Long-COVID: Randomized Crossover Exploratory Pilot Study.
A prospective, open label, randomized, crossover, pilot, exploratory study to describe the effect of the Inogen One® G4 POC on brain hypoxia, peripheral oxygen saturation and cognitive function in adults with longterm- COVID.
- Trial name
- RESTORE (NCT05212831)
- Testing
- Inogen One® G4
- Where
- 2 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Inogen Inc.
SARS-CoV-2 Acute Respiratory Disease
Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19)
A multicenter study, using prospectively collected, fresh (Category I) and frozen (Category II), residual/leftover nasopharyngeal (NP) swab in UTM/UVT specimens obtained from symptomatic individuals suspected of COVID-19…
- Trial name
- NCT06360757
- Testing
- NeuMoDx SARS-CoV-2 Assay
- Where
- United Kingdom
- Volunteers
- 503 people
- Sponsor
- QIAGEN Gaithersburg, Inc
COVID-19
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection.
- Trial name
- NCT05047601
- Testing
- PF-07321332, Ritonavir
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 2,954 people
- Sponsor
- Pfizer
Long COVID
A Study to Assess Anktiva in Patients With Long Covid-19.
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
- Trial name
- INTERRUPT_LC (NCT07108036)
- Testing
- N-803 (IL-15 Superagonist)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
COVID-19 Disease, SARS Pneumonia
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)
This prospective, single-center, randomized, placebo-controlled, observer-blind Phase 1/2 study includes two separate parts. Part 1 is a first-in-human, Phase 1 study designed to evaluate the safety, tolerability and…
- Conditions
- COVID-19 Disease, SARS Pneumonia, Pneumonia, Viral, COVID-19 Vaccine
- Trial name
- NCT04830800
- Testing
- COVIVAC, Phosphate-buffered saline
- Where
- Vietnam
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
COVID - 19, SARS CoV-2
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations.
- Trial name
- NCT07416539
- Testing
- COVID-19 Vaccines
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy
Healthy
Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use
The purpose of this Pre-approval access (PAA) program is to provide VAC31518 (Ad26.CoV2.S) vaccine for the prevention of coronavirus disease-2019 (COVID-19) infection.
- Trial name
- NCT04817657
- Testing
- Ad26.COV2.S
- Sponsor
- Janssen Research & Development, LLC
COVID-19
Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (500 mg/ 5 days) to treat moderate to severe COVID-19 pneumonia.
- Trial name
- NCT04329572
- Testing
- Hydroxychloroquine Sulfate, Azithromycin Tablets
- Where
- Brazil
- Volunteers
- 400 people
- Sponsor
- Azidus Brasil
COVID-19, SARS-COV-2 Infection
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect…
- Trial name
- NCT07300839
- Testing
- BNT162b2 Vaccine
- Where
- 196 sites in United States
- Volunteers
- 5,240 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Coronavirus Disease (COVID-19)
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection.
- Trial name
- MOVe-AHEAD (NCT04939428)
- Testing
- Molnupiravir
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,441 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, SARS CoV 2 Infection
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
This clinical trial is designed to assess the safety, tolerability and immunogenicity of a single dose of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 vaccines as a booster dose, given at least 3 months after receipt of a previous…
- Trial name
- NCT05605470
- Testing
- ChulaCov19 BNA159 vaccine (50 mcg), Pfizer/BNT vaccine (30 mcg), COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)
- Where
- 5 sites in Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Technovalia, Pty Ltd
Novel Coronavirus Pneumonia
Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19
This study was conducted in a randomized, double-blind, placebo-controlled, multicenter clinical trial design. Two groups were designed, the experimental group and the placebo control group.
- Trial name
- NCT05305456
- Testing
- Tanreqing capsule, Tanreqing capsule simulator
- Where
- 2 sites in China
- Volunteers
- 480 people
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
SARS-CoV-2 Infection, Influenza A
Project STARFISH - PRJ0002679
This is a non-interventional study to perform the clinical performance evaluation of the Starfish Test using prospectively collected matched nasopharyngeal and nasal swab samples from the same donor.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
- Trial name
- STARFISH (NCT05727202)
- Testing
- The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
- Where
- 17 sites in United States
- Volunteers
- 1,909 people
- Sponsor
- Thermo Fisher Scientific, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.